Sulfonylurea Compounds

• 

  Subject Areas on Research

  • A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005. 
  • Are sulfonylureas passé? 
  • Association of Systemic Medication Use With Intraocular Pressure in a Multiethnic Asian Population: The Singapore Epidemiology of Eye Diseases Study. 
  • Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. 
  • Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. 
  • Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes. 
  • Capsule Commentary on Min et al., Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes: How to Escalate Therapy for Patients who Fail Sulfonylureas. 
  • Cryptococcus neoformans Ilv2p confers resistance to sulfometuron methyl and is required for survival at 37 degrees C and in vivo. 
  • Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet. 
  • Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. 
  • Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: An analysis of Medicare claims data from 2007 to 2015. 
  • Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group. 
  • Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. 
  • Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin. 
  • Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. 
  • Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes. 
  • Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. 
  • Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers. 
  • Sulfonylurea Prescribing Patterns After the Introduction of DPP-4 Inhibitors and GLP-1 Receptor Agonists. 
  • Treatment of diabetes mellitus: implications of the use of oral agents.